CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

UAE Crescent Enterprises’ CE-Ventures invests in London startup Oyster Therapeutics

By Zawya

By Staff Writer

UAE-based Crescent Enterprises’ CE-Ventures has invested in London-based biotech firm Oyster Therapeutics, formerly Kesmalea Therapeutics.

The venture capital platform participated in the UK company’s $60 million Series A-2 funding round to advance targeted protein degraders for neurodegenerative diseases such as Alzheimer’s.

The investment round was led by 4BIO Capital, a London-based specialist life science VC fund, with participation from Actium Group, Eli Lilly and Company and TOHO Ventures.

The funding round also drew participation from existing investors Syncona, Oxford Science Enterprises (OSE), Mission BioCapital and MGB Ventures.

(Writing by Cleofe Maceda. Editing by Seban Scaria)
(seban.scaria@lseg.com )

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk